Zysis Limited

What Zysis Limited does

Zysis Limited is a United Kingdom-based pharmaceutical company incorporated in 2006 and headquartered in Beeston, with a stated mission of optimizing therapies for disorders of the central nervous system (CNS) to improve patient outcomes. The company operates as a small private entity with 1-10 employees, indicating a micro-cap or virtual-pharma operating model. Its commercial and scientific positioning centers on CNS therapy optimization, suggesting activity in drug reformulation, repurposing, or adjunctive therapy development, though the source data does not disclose specific pipeline assets, indications, or development stage.

The company's capital formation history is thin: a single early-stage funding engagement with Catapult Ventures in January 2007, with no subsequent funding rounds or capital raise data disclosed. Leadership is structured around a non-executive chairman (Peter Cozens) and a VP – Commercial (Russ Pendleton), consistent with a lean governance model typical of early-stage biotech. The public corporate website is registered at zysis.com, although a significant portion of the aggregated source material describing Atom.com domain marketplace features, pricing tiers, and customer segments pertains to a third-party domain listing for Zysis.com rather than to Zysis Limited's actual operations and should not be conflated with the company's business model. No products, partnerships, regulatory milestones, or revenue disclosures are present in the source data for Zysis Limited as a pharmaceutical entity.

Name

Zysis Limited

Legal name

Zysis Limited

Website

https://zysis.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

Zysis Limited is a small UK private pharmaceutical company founded in 2006 that focuses on optimizing therapies for central nervous system disorders, operating with 1-10 employees from Beeston.

Ownership category

akta.pro rank

Product category

CNS Pharmaceutical Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Central nervous system therapeutics
• Pharmaceutical therapy optimization
• CNS disorder treatments
• Pharmaceutical R&D services
• Neurology drug development

Headquarters

HQ city

Beeston

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Pricing tiers

Distribution channels1 record

Marketing channels4 records

Core offering

Zysis Limited is a UK-based pharmaceutical company that optimizes therapies for disorders of the central nervous system (CNS) to improve sufferers' lives. The company focuses on developing and refining treatment approaches targeting neurological and CNS-related conditions. Founded in 2006 and headquartered in Beeston, United Kingdom, Zysis operates as a small private pharmaceutical R&D entity (1-10 employees).

Product overview

Zysis Limited does not have products or services described in the source material. The source is an Atom.com marketplace listing for the premium domain Zysis.com, which is being offered for sale as a domain name rather than representing Zysis Limited's own product portfolio.

Differentiator

Problem solved

Functional benefit

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves3 records

Broad incumbents

• H. Lundbeck: Large global Danish pharmaceutical company fully dedicated to CNS disorders including depression, schizophrenia, Alzheimer's, and Parkinson's. Comparable as a broad incumbent CNS pharma that smaller UK CNS developers like Zysis would typically partner with or license to.
• Otsuka Pharmaceutical: Global pharmaceutical company with a major CNS and mental-health franchise (including aripiprazole and digital therapeutics). Comparable as a broad incumbent acquirer/partner for CNS-focused small pharma assets.

Emerging players

• Beckley Psytech: UK-based clinical-stage CNS company developing psychedelic medicines for neuropsychiatric conditions. Comparable as a small UK CNS therapeutics innovator in psychiatry.
• Karuna Therapeutics: CNS-focused biotech developing xanomeline-trospium for schizophrenia and other psychosis indications, recently partnered/acquired by BMS. Comparable as a small CNS therapeutics company with a therapy-optimization angle (reformulation of an older molecule).
• Compass Pathways: UK-based mental-health therapeutics company developing psilocybin-based treatments for treatment-resistant depression. Comparable as a UK-anchored CNS/psychiatry-focused pharmaceutical developer.
• BenevolentAI: AI-driven drug discovery company with significant CNS pipeline activity, including partnerships with large pharma. Comparable as a UK- and Europe-based CNS therapeutics innovator leveraging advanced technology to accelerate CNS discovery.
• Small Pharma: UK-based clinical-stage CNS biotech developing psychedelic-assisted therapies for depression. Comparable as a small UK-headquartered CNS therapeutics developer focused on optimizing mental-health treatments.

Direct peers

• GW Pharmaceuticals: UK-based CNS-focused pharmaceutical company that developed cannabinoid therapies for epilepsy and multiple sclerosis before being acquired by Jazz Pharmaceuticals. Directly comparable as a UK-incorporated CNS innovator with a therapy-optimization angle.
• Autifony Therapeutics: UK-based small-molecule CNS biotech focused on neuronal ion-channel modulators for disorders such as schizophrenia and hearing disorders. Directly comparable as a small UK CNS therapeutics developer.
• Heptares Therapeutics (Sosei Heptares): UK-based CNS-focused biotech developing novel small molecules targeting GPCRs for neurological and psychiatric diseases. Directly comparable as a UK CNS therapeutics company, though larger and more platform-oriented.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zysis Limited